Formulation and stability study of hydroxychloroquine sulfate oral suspensions.
Pharm Dev Technol
; 26(3): 328-334, 2021 Mar.
Article
in English
| MEDLINE | ID: covidwho-1020096
ABSTRACT
Hydroxychloroquine is an antimalarial drug indicated in the treatment of acute attacks of malaria due to Plasmodium vivax, P. malariae, P. ovale, and susceptible strains of P. falciparum. It is also used for the treatment of rheumatoid arthritis, discoid and systemic lupus erythematosus, and more recently proposed in COVID-19 therapy. Hydroxychloroquine is only available in tablets which are not easy to administer for pediatric and geriatric patients, and patients unable to swallow such as patients found in intensive care units. The aim of this work was to develop and optimize a ready to use liquid hydroxychloroquine formulation and to carry out the corresponding chemical and microbiological stability studies. The formulation was evaluated for ease of preparation, physical properties, and palatability. Its stability was performed at ambient temperature and under refrigeration. After 6 months of stability testing, the results showed no pH change, no drug loss, no microbial development, and no visual change. The formulation, employing excipients in a range that EMA has recommended, showed chemical and microbiological stability for at least 6 months even in the worst storage conditions.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
COVID-19 Drug Treatment
/
Hydroxychloroquine
/
Antimalarials
Type of study:
Experimental Studies
Limits:
Humans
Language:
English
Journal:
Pharm Dev Technol
Journal subject:
Pharmacy
Year:
2021
Document Type:
Article
Affiliation country:
10837450.2021.1871918
Similar
MEDLINE
...
LILACS
LIS